92921 LCMS TDM Series A Antiepileptic Drugs

Parameter Set Antiepileptic Drugs - LC-MS/MS

  • 10,11-Dihydroxycarbamazepine
  • 10-OH-carbamazepine
  • Carbamazepine
  • Carbamazepine-10,11-epoxide
  • Ethosuximide
  • Felbamate
  • Gabapentin
  • Lacosamide
  • Lamotrigine
  • Levetiracetam (Keppra®)
  • N-Desmethylmesuximide
  • Oxcarbamazepine
  • Phenobarbital
  • Phenylethylmalonamide (PEMA)
  • Phenytoin
  • Pregabalin
  • Primidone
  • Rufinamide
  • Stiripentol
  • Sultiame
  • Theophylline
  • Tiagabine
  • Topiramate
  • Valproic acid
  • Vigabatrin
  • Zonisamide

Order no.: 92921, 92111, 92110

Encompasses 26 analytes
3PLUS1® Multilevel Calibrator Set available
Part of the MassTox® TDM Series A
Method for automated sample preparation also available

Product Name Qty
Parameter Set - Antiepileptic Drugs - LC-MS/MS
Order no.: 92921
BASIC Kit A for 200 tests - LC-MS/MS
Order no.: 92111/200
BASIC Kit A for 1000 tests - LC-MS/MS
Order no.: 92111/1000
BASIC Kit A for 1000 tests with 96 Well Filter Plates - LC-MS/MS
Order no.: 92111/1000/F
MassTox® TDM MasterColumn® A
Order no.: 92110


Clinical relevance

Epileptic seizures are the result of synchronous discharges of neuron groups in the brain that can lead to sudden and involuntary stereotypical behavioural or sensory disorders. Numerous types of seizures have been described, each of which requires specialised therapy. The probability of them occurring depends on a number of factors. In addition to genetic predisposition, it is primarily exogenous factors that are relevant, such as accident, thrombosis, tumours or meningitis. Therapy with anticonvulsive medication (antiepileptics) leads to a reduction in seizures and sometimes even a complete elimination of seizures in most treated patients. The precondition for the antiepileptics to have a therapeutic effect is usually patient compliance, which means regular use of the medication. Thus, monitoring of the blood levels is essential, especially during initial dose setting.


Product advantages

With the Parameter Set Antiepileptics in serum/plasma, 26 different drugs can be measured quickly and efficiently using LC-MS/MS. Due to the careful optimisation of all kit components as well as the chromatographic separation, matrix effects (“ion suppression”) are minimised and the robustness of the method is enhanced. Sample preparation is based on a protein precipitation step. The use of stable isotopically labelled (deuterated) and co-eluting internal standards as well as 3PLUS1® multilevel calibrators ensures high precision and the reproducible and reliable quantification of the analytes. The method is comprehensively validated.

The Parameter Set is a part of the Series A modular system, which enables the analysis of more than 170 parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory. The Basic Kit A contains all components required for sample preparation and all necessary mobile phases. The MasterColumn® A is the analytical column used for the determination of all Series A analytes. Our portfolio contains further MassTox® Parameter Sets for covering more than 170 substances and metabolites.


Technical Data

Method of Analysis



10,11-Dihydroxycarbamazepine, 10-OH-carbamazepine, Carbamazepine, Carbamazepine-10,11-epoxide, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam (Keppra®), N-Desmethylmesuximide, Oxcarbamazepine, Phenobarbital, Phenylethylmalonamide (PEMA), Phenytoin, Pregabalin, Primidone, Rufinamide, Stiripentol, Sultiame, Theophylline, Tiagabine, Topiramate, Valproic acid, Vigabatrin, Zonisamide

Analysis Time

2.5 - 3.5 min

Limit of quantification

0.1–7.0 mg/l


1–300 mg/l


84–115 %


CV = 2–8 %


CV = 4–9 %


Starting point: 0% Mobile Phase 2

Group 1
0.00→2.00 min, 100 % Mobile Phase 2
2.00-2.60 min, 100 % Mobile Phase 2
2.61-3.50 min, 0 % Mobile Phase 2

Group 2 and 3
0.00→1.00 min, 100 % Mobile Phase 2
1.00-1.60 min, 100 % Mobile Phase 2
1.61-2.50 min, 0 % Mobile Phase 2

Group 4 and 5
0.00→1.00 min, 100 % Mobile Phase 2
1.00-1.80 min, 100 % Mobile Phase 2
1.81-2.70 min, 0 % Mobile Phase 2



Pre-analytic Treatment

Stored in the dark and cooled at +4 °C patient specimens are stable for at least 24 hours. For longer storage periods keep them frozen at approx. -20 °C.

Sample Preparation

  • Add 800 µl Internal Standard Mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 µl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 µl Extraction Buffer, mix briefly (vortex) and incubate 2 min
  • Add 250 µl of mixture A, mix 30 s (vortex) and centrifuge 5 min
  • Dilute supernatant with Dilution Buffer (depending on instrument sensitivity) and inject into LC-MS/MS system

Sample Stability

Samples are stable up to 1 week at +2 to +8 °C. For longer storage periods keep samples frozen below -18 °C.

Injection Volume

0.2 – 50 µl


ESI positive and negative



Additional Info

We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.

Please note

The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.

Kit Components


Calibrators available separately